This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Friday's Health Winners & Losers

After an enthusiastic midweek hop, biotech stocks rounded out a blasé end-of-week performance with business updates and legal matters Friday.

Celera (CRA), however, emerged as a winner. The company said Friday it received a $2 million milestone payment from Merck (MRK) for the advancement of odanacatib for osteoperosis into a phase III clinical trial.

Celera, an Applera (ABI) subsidiary, and Merck have had a collaboration agreement since 1996 on a program targeting cathepsin K, an enzyme believed to play a role in osteoperosis. Merck has been sole responsible for research and development since February 2003.

Celera shares gained 3.7% to $14.05. Applera was unchanged. Merck was 1.2% lower at $51.65.

Other stocks dealt with the aftermath of business updates:

Idenix Pharmaceuticals (IDIX) lost ground after announcing a restructuring plan to focus on hepatitis C virus (HCV) and HIV programs. The company amended an agreement with Novartis (NVS) to discontinue all activities for hepatitis B treatment Tyzeka and cutting a third of its workforce. The plan is expected to result in annual savings of $40 million to $45 million.

Idenix, a component of the Nasdaq biotechnology index, lost 17 cents, or 5.6%, to $2.86. The index was down 5.03, or 0.6%, to 854.37.

Also on the way down was Par Pharmaceuticals (PRX), which said it expects lower earnings as competitive pressures have resulted in scaled back sales of several products. It gave guidance of between 95 cents a share and $1.10 a share -- or between $1.05 and $1.20 a share after one-time events -- on revenue of $730 million to $765 million. The Thomson Financial consensus target was $1.56 a share.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,220.76 +63.91 0.37%
S&P 500 2,009.69 +8.12 0.41%
NASDAQ 4,584.8890 +22.70 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs